Abstract
Objectives: The study aimed to evaluate the pharmacoeconomic impact of gastro-protective agents (GPA) by carrying out cost-benefit analysis (CBA) and cost-effective analysis (CEA). Methods: This prospective observational study was carried out by simple randomization technique at Karnataka Institute of Medical Science, Hubballi. Data used were socio-economic details based on modified B. G Prasad scale. Current Index of Medical Specialists updated version March 2021 was used for CBA and CEA. Regression analysis was the statistical tool used in the study. Results: A total of 120 participants were included in the study. 57.5% were male and 42.5% were female. 3.33% were pediatrics, 32.5% were young adults, 37.5% were elder adults and 26.67% were geriatrics. Out of 120 samples, 94 participants were prescribed with pantoprazole, other drugs prescribed include domperidone and pantoprazole, rabeprazole, and ranitidine. The CBA revealed ratio of benefits over costs for pantoprazole was 3.86, ranitidine was 9.31, pantoprazole and domperidone was 0.84 and rabeprazole was 0.84. Additional cost of 138.30 Indian Rupee must be spent on pantoprazole over ranitidine to get cost-effective treatment without disease for one whole year. Conclusion: The CBA revealed that maximum patients received benefits for pantoprazole. CEA gives an idea on best effective treatment over two drugs of different class. Our study concludes that pantoprazole is deemed to be superior over other drugs of GPA prescribed among study participants.
Highlights
The ability of a pharmacological treatment to minimize or prevent gastric mucosal injury/necrosis caused by a range of ulcerogenic and necrotizing agents is known as gastro-protection [1]
Techniques used in Pharmacoeconomics are cost-minimization analysis (CMA), cost-effectiveness analysis (CEA), cost-utility analysis, cost-benefit analysis (CBA), cost of illness analysis
Pantoprazole has lesser pharmacoeconomic burden when compared to other pump inhibitor (PPI) monotherapy and combination therapy
Summary
The ability of a pharmacological treatment to minimize or prevent gastric mucosal injury/necrosis caused by a range of ulcerogenic and necrotizing agents is known as gastro-protection [1]. PPIs non-competitively antagonize H+/K+ adenosine triphosphatase (ATPase), the enzyme in gastric parietal cells responsible for transporting H+ ions into the gastric lumen. Different doses of these drugs are recommended, but at equivalent doses, these agents are remarkably similar when used in the treatment of acid-related disorders. They help in the prevention of NSAID associated ulcers. Pharmacoeconomics is research on health outcome as it is a patientcentered outcome increasing the quality of life (QOL) in years especially when comparing a non-pharmacological therapy or preventive methods such as surgical and screening interventions. The quality-adjusted lifeyear (QALY) has a major outcome in making clinical decisions [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
